Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-09-24. The company is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The company is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Follow-Up Questions
Who is the CEO of Profound Medical Corp?
Dr. Arun Menawat is the Chairman of the Board of Profound Medical Corp, joining the firm since 2015.
What is the price performance of PROF stock?
The current price of PROF is $4.13, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Profound Medical Corp?
Profound Medical Corp belongs to Health Care industry and the sector is Health Care
What is Profound Medical Corp market cap?
Profound Medical Corp's current market cap is $124.1M
Is Profound Medical Corp a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Profound Medical Corp, including 1 strong buy, 4 buy, 1 hold, 0 sell, and 1 strong sell
